Developer docs
API playgroundTry for free, no card

Search company profiles

Neoleukin Therapeutics

Full company profile

uuid0007671

Namestring
Neoleukin Therapeutics
Legal namestring
Neoleukin Therapeutics
Websiteurl
neoleukin.com
Company typeenum
Public
Founded yearint
2003
Descriptiontext

Neoleukin Therapeutics is a publicly traded, clinical-stage pharmaceutical company (NASDAQ: NLTX) headquartered in Seattle, Washington, focused on developing medicines to treat serious immunological disorders. Founded in 2003, the company employs between 51 and 100 people and operates as an independent, publicly-held entity with no disclosed parent company or subsidiary structure.

The company's leadership team is anchored by founder and CEO Jonathan Drachman and includes Chief Medical Officer Priti Patel, Vice President and Head of Research Bill Arthur, Director of Computational Technology Javier Castellanos, and Principal Scientist Ryan Swanson. The inclusion of a dedicated computational technology role indicates that computational biology is part of the discovery workflow, although specific product candidates, platforms, or modalities are not disclosed in the input data. No approved products, named customers, or commercialization milestones are referenced, consistent with a pre-commercial development stage.

Capitalization has been driven primarily by equity financings, with approximately $86.2M raised in December 2019 and $71.4M raised in July 2020, for cumulative disclosed funding of roughly $157.6M over an 18-month window. As a clinical-stage biotech, the business model is currently R&D-driven rather than revenue-generating: the company funds operations through equity capital and is expected to monetize through future product sales, licensing, or partnership deals once pipeline assets advance to commercialization.

Short descriptiontext

Neoleukin Therapeutics is a Seattle-based, publicly traded clinical-stage pharmaceutical company (NASDAQ: NLTX) developing medicines for serious immunological disorders. Founded in 2003, it employs 51-100 people and is funded primarily through equity financings.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
biopharmaceutical medicines, immunology therapeutics, protein therapeutics, clinical stage biotechnology, immunological disorder treatments
Industry3 codes
1Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
CodeHLAAAAAJPrimaryYes
2Immunology & Autoimmune Specialty Pharmaceuticals
CodeHLAIACABPrimaryNo
3Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
CodeHLAAAIAHPrimaryNo
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals
Social media profiles2 records
Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Neoleukin Therapeutics is a pharmaceutical company that develops medicines to treat serious immunological disorders. The company focuses on creating novel therapeutic candidates using protein engineering and computational design approaches for clinical-stage drug development.

Differentiator
Functional benefit
Problem solved
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Market position
Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neoleukin Therapeutics

Biopharmaceuticalsneoleukin.com

Neoleukin Therapeutics is a Seattle-based, publicly traded clinical-stage pharmaceutical company (NASDAQ: NLTX) developing medicines for serious immunological disorders. Founded in 2003, it employs 51-100 people and is funded primarily through equity financings.

What Neoleukin Therapeutics does

Neoleukin Therapeutics is a publicly traded, clinical-stage pharmaceutical company (NASDAQ: NLTX) headquartered in Seattle, Washington, focused on developing medicines to treat serious immunological disorders. Founded in 2003, the company employs between 51 and 100 people and operates as an independent, publicly-held entity with no disclosed parent company or subsidiary structure.

The company's leadership team is anchored by founder and CEO Jonathan Drachman and includes Chief Medical Officer Priti Patel, Vice President and Head of Research Bill Arthur, Director of Computational Technology Javier Castellanos, and Principal Scientist Ryan Swanson. The inclusion of a dedicated computational technology role indicates that computational biology is part of the discovery workflow, although specific product candidates, platforms, or modalities are not disclosed in the input data. No approved products, named customers, or commercialization milestones are referenced, consistent with a pre-commercial development stage.

Capitalization has been driven primarily by equity financings, with approximately $86.2M raised in December 2019 and $71.4M raised in July 2020, for cumulative disclosed funding of roughly $157.6M over an 18-month window. As a clinical-stage biotech, the business model is currently R&D-driven rather than revenue-generating: the company funds operations through equity capital and is expected to monetize through future product sales, licensing, or partnership deals once pipeline assets advance to commercialization.

Neoleukin Therapeutics firmographics

Firmographics
Name
Neoleukin Therapeutics
Legal name
Neoleukin Therapeutics
Website
https://neoleukin.com
Company type
Public
Founded year
2003
Operating status
Operating
Headcount range
51–100 employees
Short description
Neoleukin Therapeutics is a Seattle-based, publicly traded clinical-stage pharmaceutical company (NASDAQ: NLTX) developing medicines for serious immunological disorders. Founded in 2003, it employs 51-100 people and is funded primarily through equity financings.
Ownership category
akta.pro rank

Neoleukin Therapeutics industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro primary industry
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)
akta.pro secondary industries
Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)

Keywords

  • Biopharmaceutical medicines
  • Immunology therapeutics
  • Protein therapeutics
  • Clinical stage biotechnology
  • Immunological disorder treatments

Where Neoleukin Therapeutics is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Markets served

Neoleukin Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Neoleukin Therapeutics product offering

Product offering

Core offering

Neoleukin Therapeutics is a pharmaceutical company that develops medicines to treat serious immunological disorders. The company focuses on creating novel therapeutic candidates using protein engineering and computational design approaches for clinical-stage drug development.

Differentiator

Problem solved

Functional benefit

Companies that use Neoleukin Therapeutics

Customer profile

Ideal customer profiles1 record

Neoleukin Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Neoleukin Therapeutics partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights3 records

Neoleukin Therapeutics competitors and assessment

Company assessment

Market position

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Neoleukin Therapeutics social profiles

Digital presence

Neoleukin Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neoleukin Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

Neoleukin Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neoleukin Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neoleukin Therapeutics

What does Neoleukin Therapeutics do?

Neoleukin Therapeutics is a pharmaceutical company that develops medicines to treat serious immunological disorders. The company focuses on creating novel therapeutic candidates using protein engineering and computational design approaches for clinical-stage drug development.

Is Neoleukin Therapeutics a public or private company?

Neoleukin Therapeutics is a public company. It is classified as public and is currently operating.

When was Neoleukin Therapeutics founded?

Neoleukin Therapeutics was founded in 2003. It employs 51 to 100 people.

Where is Neoleukin Therapeutics based?

Neoleukin Therapeutics is headquartered in Seattle, United States, in the North America region.

Does Neoleukin Therapeutics have an API?

No public API is recorded for Neoleukin Therapeutics.

What industry is Neoleukin Therapeutics in?

Neoleukin Therapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds), with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldNeoleukin Therapeutics (NASDAQ:NLTX) & Zymeworks (NASDAQ:ZYME) Critical ContrastThis article compares two small-cap NASDAQ-listed biopharmaceutical companies: Neoleukin Therapeutics and Zymeworks, analyzing their financial metrics, valuation, and investment potential across 14 different factors. Zymeworks beats Neoleukin Therapeutics on 11 of the 14 factors compared, including analyst recommendations, institutional ownership, and profitability metrics.NeurogeneNeurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million – Neurogene Inc.Neurogene Inc. completed its merger with Neoleukin Therapeutics and concurrently closed a $95 million private financing round, resulting in a combined cash position of approximately $200 million. The transaction allows the company to advance its EXACT gene therapy portfolio, specifically the Phase 1/2 trial for NGN-401 targeting Rett syndrome, into the second half of 2026. Interim clinical data for NGN-401 is expected in the fourth quarter of 2024.GlobeNewswireNeoleukin Therapeutics Announces 1-for-4 Reverse Stock SplitNeoleukin Therapeutics approved a 1-for-4 reverse stock split, effective December 18, 2023, to comply with Nasdaq's $4.00 minimum bid price. The split reduces shares from about 9.4 million to 2.35 million, and the company will trade as Neurogene Inc. under symbol NGNE after the merger.BioSpaceNeoleukin Therapeutics Announces 1-for-4 Reverse Stock SplitNeoleukin Therapeutics announced that its Board of Directors approved a 1-for-4 reverse stock split to ensure compliance with Nasdaq's minimum bid price requirements ahead of an anticipated merger with Neurogene Inc. The split, which will reduce outstanding shares from approximately 9.4 million to 2.3 million, is set to take effect on December 18, 2023, with trading under the new name Neurogene Inc. and symbol NGNE beginning on December 19, 2023.PR NewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HCCI, CCF, SCU, NLTXHalper Sadeh LLC, an investor rights law firm, announced investigations into four pending corporate transactions for potential violations of federal securities laws or breaches of fiduciary duties: Heritage-Crystal Clean being acquired by J.F. Lehman & Company for $45.50 per share, Chase Corporation being acquired by KKR for $127.50 per share, Sculptor Capital Management being acquired by Rithm Capital Corp. for $11.15 per share, and Neoleukin Therapeutics merging with Neurogene Inc. The law firm may seek increased consideration, additional disclosures, or other relief on behalf of shareholders of the subject companies.BenzingaNeoleukin Therapeutics To Merge With Neurogene: Creates Biotech Firm Focused On Genetic Medicines For NeuNeoleukin Therapeutics Inc has agreed to merge with Neurogene Inc in an all-stock transaction, creating a combined biotech company focused on genetic medicines for neurological conditions. The combined entity will operate under the Neurogene name with approximately $200 million in cash following the merger and a concurrent $95 million oversubscribed private financing. Pre-merger Neoleukin stockholders will own approximately 16% of the combined company, which is expected to close in the fourth quarter of 2023.BioSpaceNeurogene and Neoleukin Announce Definitive Merger AgreementNeurogene Inc. and Neoleukin Therapeutics, Inc. have entered into a definitive all-stock merger agreement to combine their operations, with the resulting entity retaining the Neurogene name and trading under the ticker NGNE on Nasdaq. The transaction includes a concurrent $95 million private financing round, providing the combined company with approximately $200 million in cash to fund its pipeline through the second half of 2026.BenzingaNeoleukin Therapeutics Seeks Strategic Alternatives, To Layoff More In Round 2 Within 6 MonthsNeoleukin Therapeutics has engaged SVB Securities to review strategic alternatives and announced a second round of workforce reductions, cutting approximately 70% of staff, following a 40% reduction in November 2022. The company also discontinued development of its lead candidate NL-201 after Phase 1 monotherapy data did not demonstrate significant immunogenicity. Chief Executive Officer Jonathan Drachman will step down after a transition period, with the layoffs expected to be completed in the first half of 2023.GlobeNewswireNeoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership TransitionNeoleukin Therapeutics engaged SVB Securities to explore strategic alternatives, including a sale, merger, or divestiture. The company approved a workforce reduction of about 70% and CEO Jonathan Drachman's departure, with the cut expected in the first half of 2023.GlobeNewswireNeoleukin Therapeutics Announces Second Quarter 2022 Financial Results & Provides Corporate UpdateNeoleukin Therapeutics reported a net loss of $15.7 million for the second quarter of 2022 while maintaining a cash position of $116.5 million to fund operations through 2023. The company announced that it has added two new cytokine mimetics to its discovery pipeline using machine learning and anticipates disclosing interim data from its Phase 1 trial of NL-201 in 2023. Additionally, Neoleukin began testing NL-201 in combination with Merck’s pembrolizumab in mid-May as part of an ongoing study evaluating safety and efficacy in patients with advanced solid tumors.